Cargando…
Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study
Despite recent advances in the treatment of advanced non–small-cell lung cancer (NSCLC), bevacizumab plus platinum–based doublet chemotherapy remains a commonly used first-line regimen. This study was conducted to compare the efficacy and safety of pemetrexed–platinum with or without bevacizumab in...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138310/ https://www.ncbi.nlm.nih.gov/pubmed/34025415 http://dx.doi.org/10.3389/fphar.2021.649222 |
_version_ | 1783695778899820544 |
---|---|
author | Li, Xin Huang, Jie Qiu, Yao Zhang, Qianyun Yang, Shaoyu Wu, Kan Wang, Jiaoli Wang, Limin Ye, Jian Ma, Shenglin Xia, Bing Chen, Xueqin |
author_facet | Li, Xin Huang, Jie Qiu, Yao Zhang, Qianyun Yang, Shaoyu Wu, Kan Wang, Jiaoli Wang, Limin Ye, Jian Ma, Shenglin Xia, Bing Chen, Xueqin |
author_sort | Li, Xin |
collection | PubMed |
description | Despite recent advances in the treatment of advanced non–small-cell lung cancer (NSCLC), bevacizumab plus platinum–based doublet chemotherapy remains a commonly used first-line regimen. This study was conducted to compare the efficacy and safety of pemetrexed–platinum with or without bevacizumab in Chinese chemo-naive advanced lung adenocarcinoma patients in a real-world setting. We retrospectively collected 100 patients who received pemetrexed–platinum with or without bevacizumab (PP, n = 46; Bev+PP, n = 54) until disease progression or unacceptable toxicity. Clinical characteristics of patients were balanced, except for the proportion of stage IV b+c (Bev+PP and PP: 67.4 vs. 37.0%, p = 0.0066). Bev+PP significantly improved the objective response rate (ORR, 65 vs. 30%, p = 0.0004) and progression-free survival (PFS, 7.4 vs. 6.8 months, p = 0.009), but not overall survival (OS, 17.5 vs. 15.0 months, p = 0.553) compared with PP. Treatment (p = 0.001), gender (p = 0.008), adrenal metastasis (p = 0.001), and liver metastasis (p = 0.013) were independent risk factors for PFS. Patients with adrenal metastasis tended to be at the highest risk of not benefiting from bevacizumab addition (HR [95% CI]: 2.244 [0.6495–7.753]). The safety profile was acceptable, and grade ≥3 toxicity occurred similarly. This study showed that pemetrexed–platinum plus bevacizumab was effective compared to chemotherapy alone in Chinese patients with advanced NSCLC. |
format | Online Article Text |
id | pubmed-8138310 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81383102021-05-22 Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study Li, Xin Huang, Jie Qiu, Yao Zhang, Qianyun Yang, Shaoyu Wu, Kan Wang, Jiaoli Wang, Limin Ye, Jian Ma, Shenglin Xia, Bing Chen, Xueqin Front Pharmacol Pharmacology Despite recent advances in the treatment of advanced non–small-cell lung cancer (NSCLC), bevacizumab plus platinum–based doublet chemotherapy remains a commonly used first-line regimen. This study was conducted to compare the efficacy and safety of pemetrexed–platinum with or without bevacizumab in Chinese chemo-naive advanced lung adenocarcinoma patients in a real-world setting. We retrospectively collected 100 patients who received pemetrexed–platinum with or without bevacizumab (PP, n = 46; Bev+PP, n = 54) until disease progression or unacceptable toxicity. Clinical characteristics of patients were balanced, except for the proportion of stage IV b+c (Bev+PP and PP: 67.4 vs. 37.0%, p = 0.0066). Bev+PP significantly improved the objective response rate (ORR, 65 vs. 30%, p = 0.0004) and progression-free survival (PFS, 7.4 vs. 6.8 months, p = 0.009), but not overall survival (OS, 17.5 vs. 15.0 months, p = 0.553) compared with PP. Treatment (p = 0.001), gender (p = 0.008), adrenal metastasis (p = 0.001), and liver metastasis (p = 0.013) were independent risk factors for PFS. Patients with adrenal metastasis tended to be at the highest risk of not benefiting from bevacizumab addition (HR [95% CI]: 2.244 [0.6495–7.753]). The safety profile was acceptable, and grade ≥3 toxicity occurred similarly. This study showed that pemetrexed–platinum plus bevacizumab was effective compared to chemotherapy alone in Chinese patients with advanced NSCLC. Frontiers Media S.A. 2021-05-07 /pmc/articles/PMC8138310/ /pubmed/34025415 http://dx.doi.org/10.3389/fphar.2021.649222 Text en Copyright © 2021 Li, Huang, Qiu, Zhang, Yang, Wu, Wang, Wang, Ye, Ma, Xia and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Li, Xin Huang, Jie Qiu, Yao Zhang, Qianyun Yang, Shaoyu Wu, Kan Wang, Jiaoli Wang, Limin Ye, Jian Ma, Shenglin Xia, Bing Chen, Xueqin Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study |
title | Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study |
title_full | Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study |
title_fullStr | Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study |
title_full_unstemmed | Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study |
title_short | Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study |
title_sort | pemetrexed-platinum with or without bevacizumab for chinese chemo-naive advanced lung adenocarcinoma patients: a real-world study |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138310/ https://www.ncbi.nlm.nih.gov/pubmed/34025415 http://dx.doi.org/10.3389/fphar.2021.649222 |
work_keys_str_mv | AT lixin pemetrexedplatinumwithorwithoutbevacizumabforchinesechemonaiveadvancedlungadenocarcinomapatientsarealworldstudy AT huangjie pemetrexedplatinumwithorwithoutbevacizumabforchinesechemonaiveadvancedlungadenocarcinomapatientsarealworldstudy AT qiuyao pemetrexedplatinumwithorwithoutbevacizumabforchinesechemonaiveadvancedlungadenocarcinomapatientsarealworldstudy AT zhangqianyun pemetrexedplatinumwithorwithoutbevacizumabforchinesechemonaiveadvancedlungadenocarcinomapatientsarealworldstudy AT yangshaoyu pemetrexedplatinumwithorwithoutbevacizumabforchinesechemonaiveadvancedlungadenocarcinomapatientsarealworldstudy AT wukan pemetrexedplatinumwithorwithoutbevacizumabforchinesechemonaiveadvancedlungadenocarcinomapatientsarealworldstudy AT wangjiaoli pemetrexedplatinumwithorwithoutbevacizumabforchinesechemonaiveadvancedlungadenocarcinomapatientsarealworldstudy AT wanglimin pemetrexedplatinumwithorwithoutbevacizumabforchinesechemonaiveadvancedlungadenocarcinomapatientsarealworldstudy AT yejian pemetrexedplatinumwithorwithoutbevacizumabforchinesechemonaiveadvancedlungadenocarcinomapatientsarealworldstudy AT mashenglin pemetrexedplatinumwithorwithoutbevacizumabforchinesechemonaiveadvancedlungadenocarcinomapatientsarealworldstudy AT xiabing pemetrexedplatinumwithorwithoutbevacizumabforchinesechemonaiveadvancedlungadenocarcinomapatientsarealworldstudy AT chenxueqin pemetrexedplatinumwithorwithoutbevacizumabforchinesechemonaiveadvancedlungadenocarcinomapatientsarealworldstudy |